Sponsor study identifier
observational
11
1 country
1
Study Start
January 28, 2015
Actual (reported)Primary Completion
October 4, 2016
Actual (reported)Study Completion
September 2017
Date type not reportedThis date has not been verified as actual or estimated.
Gait and balance disturbances are one of the most incapacitating symptoms of Parkinson's disease (PD) (Boonstra et al. 2008). They can cause falls and are therefore associated with the negative spiral of (near) falls, fear of falling, fractures, reduced mobility and social isolation; hence, having a profound negative impact on quality of life (Lin et al. 2012). Originally, symptoms of PD were ascribed to dopamine deficiency and basal ganglia dysfunction (Wu et al. 2013). However, in the last decades it has become clear that other brain structures are also involved in the pathophysiology of PD (Snijders et al. 2011; Stefani et al. 2007). An intriguing, emerging insight is that the cerebellum may be involved in the pathophysiology of PD (Wu et al. 2013). That is, the cerebellum is hyperactive in PD patients during different motor tasks (Yu et al. 2007; Hanakawa et al. 1999; del Olmo et al. 2006). However, whether cerebellar hyperactivity is pathological or compensatory and how it affects gait and balance in PD patients remain open questions. Here, the investigators aim to elucidate the role of the hyperactive cerebellum in gait dysfunction in PD patients by modulating cerebellar excitability with state-of-the-art non-invasive brain stimulation techniques and investigate the effects on gait.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 2017
Date type not reportedThis date has not been verified as actual or estimated.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 26, 2015
Actual (reported)January 28, 2015
Actual (reported)January 29, 2015
Actual (reported)October 4, 2016
Actual (reported)September 2017
Date type not reportedThis date has not been verified as actual or estimated.
February 15, 2019
Actual (reported)Change in Gait Speed- Sham_On
Change in overground walking speed (10 meter walk test) after Sham transcranial direct current stimulation, participants on medication.
One session
Change in Gait Speed- Sham_Off
Change in overground walking speed (10 meter walk test) after Sham transcranial direct current stimulation, participants off medication.
One session
Change in Gait Speed- Anodal_On
Change in overground walking speed (10 meter walk test) after Anodal transcranial direct current stimulation, participants on medication.
One session
Change in Gait Speed- Anodal_Off
Change in overground walking speed (10 meter walk test) after Anodal transcranial direct current stimulation, participants off medication.
One session
People with Parkinson's disease
Kennedy Krieger Institute
Baltimore, Maryland, 21211, United States
Amy Bastian, PT, PhD
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
11 participants (actual enrollment reported by the registry).
First Submitted
January 26, 2015
First Posted
January 29, 2015
Study Start
January 28, 2015
Actual (reported)Antigen Presentation and Lymphocyte Response in Parkinson's Disease
Change in Gait Speed- Cathodal_On
Change in overground walking speed (10 meter walk test) after Cathodal transcranial direct current stimulation, participants on medication.
One session
Change in Gait Speed- Cathodal_Off
Change in overground walking speed (10 meter walk test) after cathodal transcranial direct current stimulation, participants off medication.
One session
Contact the study team to confirm eligibility.
Primary Completion
October 4, 2016
Actual (reported)Study Completion
September 2017
Date type not reportedThis date has not been verified as actual or estimated.
Last Updated
February 15, 2019
Results First Posted
February 15, 2019
Record last verified: 2017-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: